News Release

Alvotech today announced the appointment of Mark Levick as Chief Executive Officer, effective 5 August 2019. Mark brings over 18 years of global industry experience, with a very impressive track record of value creation and success in bringing new biosimilars to market. Prior to joining Alvotech, Mark was the head of development of Sandoz biopharmaceuticals. He succeeds Rasmus Rojkjaer, who has stepped down from his role.

Commenting on the appointment, Robert Wessman, Alvotech‘s Chairman and founder, said:

“Mark is the ideal candidate and brings all the necessary credentials to drive Alvotech forward. His innovative approach and strong leadership capabilities will make him a true asset for Alvotech, our customers and patients around the world who will benefit from our valuable biosimilar pipeline. Alvotech has recently reached some very important milestones in its journey to become a leading global biosimilar company, and with Mark at the helm, I am confident that we will continue to grow the business and bring new biosimilars to market.”

During his time at Sandoz, Mark oversaw the successful approval of five biosimilar medicines in major markets (etanercept, rituximab, adalimumab, infliximab and peg-filgrastim), taking Sandoz to the industry-leading position with a total of eight approved biosimilar products. Previously, Mark held roles of increasing responsibility at Novartis in the USA and Switzerland, including the global head of biologics, clinical development and respiratory development, and he played a pivotal role in the approval of innovative biopharmaceutical medicines including Xolair® for pediatric use, Ilaris® and Cosentyx®. Prior to Novartis, Mark held leadership roles in biopharmaceutical development at GlaxoSmithKline in the UK and USA and served as a medical reviewer at the UK’s Medicines and Healthcare Products Regulatory Agency and European Medicines Agency.

Mark was awarded his medical degree from the University of Newcastle, Australia, and studied at the University of Cambridge in the UK as a Commonwealth scholar. Mark holds a PhD in vaccine development from Cambridge University, and he is a fellow of the Royal College of Pathologists of Australasia and the Australasian College of Tropical Medicine.